Lonza confirms outlook as it expects more contracts in coming months
By Marleen Kaesebier (Reuters) -Swiss contract drug manufacturer Lonza confirmed its full-year guidance on Thursday after a strong third quarter for its main contract development and manufacturing organization (CDMO) business. The Basel-based company continues to expect a core earnings before interest, taxes, depreciation and amortization margin of 30% to 31% for the CDMO business in 2025. …
Lonza confirms outlook as it expects more contracts in coming months Read More »










